Comparison · NCT00385138-0869ff42
Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding. Trial comparisons, record NCT00385138-0869ff42. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00385138-0869ff42
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0545 | 0.0465 | 0.0638 | wilson | |
| Risk in group 2 | 0.0343 | 0.0281 | 0.042 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0201 | 0.00907 | 0.0313 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.59 | 1.23 | 2.05 | log | |
| Odds ratio, group 1 over group 2 | 1.62 | 1.24 | 2.12 | log | |
| Number needed to treat, for one more participant with the outcome on Cangrelor than on Clopidogrel | 49.7 | 31.9 | 110 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cangrelor | cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion | 145 | 2,662 | OG000 |
| Group 2 | Clopidogrel | placebo bolus \& infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion | 91 | 2,650 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of ACUITY Major Bleeding
- Description
- Major bleeding (non-CABG-related) - Safety population
- Time frame
- randomization through 48 hours post randomization
- Population
- Safety population
Source ClinicalTrials.gov
Trial
- Title
- Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
- NCT number
- NCT00385138
- Phases
- PHASE3
- Conditions
- Atherosclerosis, Acute Coronary Syndrome (ACS)
- Interventions
- Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
- Lead sponsor
- The Medicines Company
- Results first posted
- 2014-04-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00385138?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00385138-0869ff42